IL1B and atherosclerosis: Three prominent clinical trials published in recent years (CANTOS, COLCOT, and LodoCo2) demonstrated that targeted inhibition of the NLRP/IL1β inflammatory axis can significantly improve the prognosis of ASCVD patients, suggesting NLRP/IL1β as an ideal target for anti-inflammatory therapy of ASCVD [11–13].